EphB2 SNPs and Sporadic Prostate Cancer Risk in African American Men

Christiane M. Robbins1, Stanley Hooker2, Rick A. Kittles3, John D. Carpten1*

1 Division of Integrated Cancer Genomics, Translational Genomics Research Institute, Phoenix, Arizona, United States of America
2 Section of Genetic Medicine, Department of Medicine, Pritzker School of Medicine, The University of Chicago, Chicago, Illinois, United States of America
3 Section of Hematology/Oncology, Department of Medicine and Institute of Human Genetics, University of Illinois at Chicago, Chicago, Illinois, United States of America

Abstract

The EphB2 gene has been implicated as a tumor suppressor gene somatically altered in both prostate cancer (PC) and colorectal cancer. We have previously shown an association between an EphB2 germline nonsense variant and risk of familial prostate cancer among African American Men (AAM). Here we set out to test the hypothesis that common variation within the EphB2 locus is associated with increased risk of sporadic PC in AAM. We genotyped a set of 341 single nucleotide polymorphisms (SNPs) encompassing the EphB2 locus, including known and novel coding and noncoding variants, in 490 AA sporadic PC cases and 567 matched controls. Single marker-based logistical regression analyses revealed seven EphB2 SNPs showing statistically significant association with prostate cancer risk in our population. The most significant association was achieved for a novel synonymous coding SNP, TGen-624, (Odds Ratio (OR) = 0.22; 95% Confidence Interval (CI) 0.08–0.66, p = 1 × 10^-5). Two other SNPs also show significant associations toward a protective effect rs10465543 and rs12090415 (p = 1 × 10^-4), OR = 0.49 and 0.7, respectively. Two additional SNPs revealed trends towards an increase in risk of prostate cancer, rs4612601 and rs4263970 (p = 0.001), OR = 1.35 and 1.31, respectively. Furthermore, haplotype analysis revealed low levels of linkage disequilibrium within the region, with two blocks being associated as prostate cancer risk among our population. These data suggest that genetic variation at the EphB2 locus may increase risk of sporadic PC among AAM.

Citation: Robbins CM, Hooker S, Kittles RA, Carpten JD (2011) EphB2 SNPs and Sporadic Prostate Cancer Risk in African American Men. PLoS ONE 6(5): e19494. doi:10.1371/journal.pone.0019494

Editor: Jen-Tsan Ashley Chi, Duke University, United States of America

Received: November 2, 2010; Accepted: April 8, 2011; Published: May 16, 2011

Copyright: © 2011 Robbins, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the National Institutes of Health, National Cancer Institute, Center to Reduce Cancer Health Disparities Grant (R01CA122009) and the Department of Defense (DAMD W81XWH-07-1-0203). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: jcarpten@tgen.org

Introduction

Prostate cancer (PC) remains the most common male specific malignancy diagnosed in the U.S. In 2010 alone about 217,730 new cases of prostate cancer accounted for 28% of diagnoses for the ten leading cancer types. Furthermore, an estimated 32,050 deaths are attributed to this disease annually [1]. Many risk factors such as diet, lifestyle, hormones, age, and race have been implicated as contributing to the risk of prostate cancer; however, family history is the single most significant and reproducible risk factor known, where men with two or three first degree relatives with prostate cancer had a five and 11-fold increased risk of developing prostate cancer, respectively [2,3].

It is widely known that the incidence rate of prostate cancer varies widely by ancestry with African American Men (AAM) having among the highest prostate cancer rates in the world. The 2002–2006 incidence rate of prostate cancer in the U.S. per 100,000 men was 231.9 in AAM versus 146.3 in European American Men (EAM) [1]. This disparity is seen even more drastically when looking at the death rates amongst these two groups with AAM having a greater than two-fold higher (56.3 per 100,000) prostate cancer death rate compared to EAM (23.6 per 100,000) during this same time-frame [1]. Although it is generally accepted that socio-economic factors are major drivers of the disparity in prostate cancer incidence and mortality, biological factors may also play a role. Recent evidence supports a genetic component contributing at least in part to this racial disparity and influencing the disease progression [4]. Compelling evidence shows strong genetic association between prostate cancer risk and genetic markers at 8q24, where several of the risk alleles have minor allele frequencies that are higher within populations of recent West African decent, suggesting a role in the increased incidence of prostate cancer in AAM [5,6,7,8,9,10].

Furthermore, several genes implicated as hereditary prostate cancer tumor suppressor genes such as HPC/ELAC2 and RNASEL have been linked to increased risk of prostate cancer in African Americans [11,12,13,14]. To this end, our group has looked at the relationship between somatically altered tumor suppressor genes in prostate cancer and risk of familial prostate cancer among African American men. The EPHB2 tyrosine kinase was first reported as a prostate cancer tumor suppressor gene, harboring somatic mutations in prostate tumors [15]. Furthermore, somatic alterations at the EphB2 locus have been reported in colorectal cancer as well [16,17], further supporting a role for EphB2 as an important cancer gene. Additionally, a germline EphB2 nonsense variant (3055A>T; K1019X) was positively associated with risk of familial prostate cancer in African American men from high-risk families [18].
Although a previous association study of the EphB2 gene has focused on coding region variants in familial prostate cancer cases, we have set out to determine if genetic variation at the EphB2 locus is associated with risk of sporadic prostate cancer in African Americans. Here we report the genotyping of 341 single nucleotide polymorphisms (SNPs) encompassing the entire EphB2 locus in a population of AAM including 490 sporadic cases and 567 matched controls to search for association between EphB2 genotypes or haplotypes and risk of prostate cancer in our study population.

Results

To test for association between genetic variation at the EphB2 locus and risk of sporadic prostate cancer among AAM, we performed a detailed case/control candidate gene association study. To be comprehensive, rather than using a tagged SNP approach we chose to genotype all known SNPs encompassing the EphB2 gene within our population. We chose 355 SNPs that had been selected for genotyping by the International HapMap Project in order to develop our own haplotype map of the EphB2 gene in our specific population. These SNPs were supplemented by a set of 14 EphB2 coding SNPs previously discovered and reported by our group [18]. After assay development we ended up with a total of 341 SNPs for analysis, which were genotyped in our sample of 1,057 AAM including 490 sporadic cases and 567 matched controls. Details of the sample population can be found in Table 1. To minimize errors potentially caused by population substructuring, all individuals within our sample have been genotyped with an independent set of 10 admixture informative markers (AIMs). An initial analysis was carried out to identify SNPs that were out of Hardy-Weinberg equilibrium (HWE). A total of 26 SNPs departed from HWE (Table S1). Of the remaining 315 SNPs, 19 of them were mono-allelic in our population.

Detailed results of the association analysis for all informative SNPs are presented in Table S2. These results are further illustrated in Figure 1. Following corrections for genetic ancestry and multiple testing, we found statistically significant associations for seven SNPs within the EphB2 gene, which remained significant after multiple testing (Table 2). The most significant association was achieved for a novel synonymous coding SNP, TGen-624, (Odds Ratio [OR] = 0.22; 95% Confidence Interval [CI] 0.08–0.66, p = 1 × 10^-6), which seems to provide a protective effect. Two other SNPs show significant associations toward a protective effect including rs10465534 and rs12090415 (p = 1 × 10^-6), OR = 0.49 and 0.7, respectively. Two additional SNPs showed trends towards an increase in risk of prostate cancer, including rs4612601 and rs4263970 (p = 0.001), with OR = 1.35 and 1.31, respectively.

We also tested the possibility of whether these seven SNPs were each independent risk factors or whether the associations were dependent on each other. We performed a stepwise regression using each SNP individually as causal while controlling for the others. None of the other SNPs contributed to the association when either rsTGEN-624 or rs12090415 were considered predictors of risk.

Very little extended linkage disequilibrium (LD) was observed across the EphB2 gene (Figure 1). Instead we observed 38 small haplotype blocks (largest spanning about 20 kb). This is consistent with the findings that populations of recent West African descent have less LD and smaller block structures [32]. Haplotype association analyses were consistent with our single SNP analyses. Only three of the SNPs tested were within defined haplotype blocks (rs1318720, rs4612601, and rs10465531). Haplotype block 6, was tagged by SNPs rs138720 and rs4612601, and haplotype block 18, tagged by SNPs rs12074138 and rs10465531, were significantly associated with prostate cancer (Table 3).

Discussion

The EphB2 gene encodes the EphB receptor tyrosine kinase and was previously identified by our group as a tumor suppressor gene in prostate cancer [15]. An independent study looking at 72 probands from African American hereditary prostate cancer families identified 10 sequence variants in the EphB2 gene [18]. This included a common nonsense mutation K1019X that showed an association with PC in AA men that had a family history of PC even after adjusting for admixture. However this association was not seen in AA sporadic cases with PC [18].

Here, we undertook a study to determine if genetic variation at the EphB2 locus is associated with risk of sporadic prostate cancer among African American men. Not with standing, our comprehensive analysis of the EphB2 locus further supports the importance of the EphB2 gene as a putative tumor suppressor gene involved in the disease etiology of prostate cancer and that both common and rare EphB2 variants likely play a significant role in increased disease risk of sporadic prostate cancer in AAM. The previously identified novel synonymous coding SNP TGen-624 did not show any association of increased risk in AA men with family history of PC, however here we show that in AA men with sporadic disease there is a statistically significant association with risk. This further supports the importance of the EphB2 gene in not only AAM with familial PC but also in AAM with sporadic PC, although further validation in other datasets is needed to fully support our association.

While we are encouraged by the consistency between our current and previous results, we do note that our study is limited. First, power calculations were used to define the size of our study population, and our modest sample size is sufficient to detect moderate to large effects (OR > 1.5). However, we would be limited to detect loci with smaller effects (1.2–1.4). Furthermore, although we genotyped a relatively dense set of known SNPs (~1 SNP per 700 bp), it is possible that additional novel ‘private’ SNPs with important effects may have been missed within the EphB2 locus, supporting possible association study designs based upon whole genome or candidate region sequencing to capture the full amount of genetic variation within a given study population.

We captured much of the variation along the EphB2 gene and observed many small haplotype blocks across the gene, which suggests that the discovery of genetic associations in populations

---

**Table 1. Clinical characteristics of prostate cancer cases and controls**

| Characteristics                     | Controls | Cases | P   |
|-------------------------------------|----------|-------|-----|
| Number of participants [n (%)]      | 567      | 490   |     |
| Age in years [mean (SD)]           | 65.9 (10.5) | 65.9 (9.3) | 0.40 |
| PSA in ng/ml [mean (SD)]           | 1.9 (1.1) | 85.4 (394.2) | <0.001 |
| Gleason score [n (%)]              |          |       |     |
| <8                                 |          | 210   | (42.9) |
| ≥8                                 |          | 280   | (57.1) |
| Global west African ancestry [mean (SD)] | 0.79 (0.1) | 0.82 (0.1) | 0.001 |
of recent west African descent should rely on high resolution haplotype maps based on African populations. Therefore, genome-wide association studies using array technologies that are based on European haplotype-tagging SNPs or even those with one million evenly spaced SNPs (one SNP per 3 kilobases) may not capture the amount of genetic information needed to detect associations in genes such as EphB2 in populations of recent west African descent such as ours. We feel this study sets the stage for a new era in genome-wide association studies in populations of recent west African descent, where associations might only be detected through extremely high-resolution genetic maps.

Materials and Methods

Ethics Statement

All samples were initially collected for research purposes under a Howard University IRB-approved protocol. Written informed consent was obtained by all subjects for this Howard University study. These samples were then analyzed at the Translational Table 2. Allele frequencies and association with prostate cancer for significant EphB2 SNPs

| dbSNP ID   | Position (bp) | Gene Region | Allele | Cases | Controls | OR     | 95% CI   | P-value |
|------------|---------------|-------------|--------|-------|----------|--------|----------|---------|
| rs4263970  | 22936517      | Intron 1    | A      | 0.51  | 0.42     | 1.31   | 1.16–1.90 | 0.001   |
| rs1318720  | 22939099      | Intron 1    | G      | 0.26  | 0.35     | 0.70   | 0.54–0.92 | 0.001   |
| rs4612601  | 22939631      | Intron 1    | G      | 0.56  | 0.47     | 1.35   | 1.18–1.92 | 0.001   |
| TGEN-624   | 22983969      | -           | A      | 0.01  | 0.05     | 0.22   | 0.08–0.66 | 1×10⁻⁵  |
| rs10465531 | 23006379      | Intron 3    | A      | 0.15  | 0.22     | 0.71   | 0.51–0.94 | 0.004   |
| rs10465543 | 23006805      | Intron 3    | A      | 0.15  | 0.23     | 0.49   | 0.36–0.74 | 0.0001  |
| rs12090415 | 23027818      | Intron 3    | A      | 0.30  | 0.40     | 0.70   | 0.59–0.93 | 0.0001  |

OR (95% CI) and P-value adjusted for age and West African ancestry.
Chromosome positions according to Build 36, hg18.
doi:10.1371/journal.pone.0019494.t002
Table 3. EphB2 haplotype frequencies in three major blocks

| Block | Haaplotype Frequency | Frequency (Case, Control) | $X^2$ | P-Value |
|-------|----------------------|---------------------------|-------|---------|
| Block 6 rs1318720, rs4612601 | AG | 0.496 | 0.555, 0.464 | 11.59 | 0.0007 |
| | GA | 0.316 | 0.260, 0.345 | 11.55 | 0.0007 |
| | AA | 0.185 | 0.182, 0.187 | 0.05 | 0.8229 |
| Block 18 rs12074138, rs10465531 | AG | 0.573 | 0.590, 0.565 | 0.89 | 0.3456 |
| | GG | 0.232 | 0.257, 0.223 | 2.17 | 0.1401 |
| | AA | 0.194 | 0.151, 0.211 | 8.09 | 0.0044 |
| Block 19 rs12133964, rs1440576, rs4655117 | GGG | 0.394 | 0.403, 0.388 | 0.33 | 0.5632 |
| | GAG | 0.365 | 0.394, 0.355 | 2.20 | 0.1377 |
| | AGA | 0.188 | 0.147, 0.204 | 7.47 | 0.0063 |
| | GGA | 0.045 | 0.050, 0.043 | 0.41 | 0.5211 |

Genomics Research Institute under a protocol approved by Western Institutional Review Board (WIRB). As the samples had already been collected for the Howard University study, a waiver of consent was granted by WIRB for use of the samples in this protocol without additional consent from study participants.

African American sporadic prostate cancer cases and controls

Unrelated men (N = 1,057) self-described as African American were recruited between the years 2001 and 2005 from the Division of Urology at Howard University Hospital (HUH) in Washington, DC. Incident prostate cancer cases (N = 490) were identified by urologists within the division or study coordinator and confirmed by review of medical records. Control subjects (N = 567) unrelated to the cases and matched for age (±5 years) were also ascertained from the PC screening population of the Division of Urology at HUH. Individuals who were ever diagnosed with benign prostatic hyperplasia (BPH) and/or had an elevated prostate specific antigen test (>2.5 ng/ml), or had an abnormal digital rectal examination (DRE) were not included as controls. The response rate among the African American cases was 90% and the response rate for the African American controls was 85%. The demographic characteristics of participants in the screening program were similar to the patient population seen in the Division of Urology clinics (Table 1). Recruitment of prostate cancer cases and controls occurred concurrently and were unmatched with respect to family history. All participants were between 40 and 85 years of age. Clinical characteristics including Gleason grade, PSA, age at diagnosis and family history were obtained for all cases from medical records. Disease aggressiveness was defined as “Low” (Gleason grade <8) or “High” (Gleason grade ≥8).

Single Nucleotide Polymorphism (SNP) genotyping

In this study we selected all SNPs (n = 355) encompassing the entire EphB2 genomic locus between the Build 36, hg18 positions of chr1:22,904,000 - 23,119,000 that were genotyped by the International HapMap (version 2) [19]. An additional 14 SNPs were included that were previously reported by our group [18]. This set of 369 SNPs was submitted for Illumina GoldenGate oligo assay pool (OPA) design, where duplicate SNPs and those that will potentially adversely affect the performance of the assay were removed. A set of 28 SNPs failed assay design, leaving us with 341 SNPs for genotyping in our study (Table S1). Genomic DNA was obtained from isolated lymphocytes using cell lysis, proteinase K-treatment, protein precipitation and DNA precipitation. DNA stocks were diluted to 10 ng/ul and genotyping was performed using the Illumina GoldenGate genotyping assay as per manufacturer’s recommendations (Illumina Inc., San Diego, CA). Genotype calls were made using BeadStudio 3 software (Illumina Inc., San Diego, CA). SNPs were excluded from the analysis if the GenTrain Score was <0.4 and the call rate was <0.95. We used a Hardy-Weiberg equilibrium cut-off of p<0.0001 because of increased admixture disequilibrium in the AA population and to take into account multiple testing. Twenty-six (26) SNPs significantly departed from HWE in our African-American samples.

Estimating genetic ancestry

The genomes of admixed populations such as African Americans are comprised of different genetic segments arising from different “parental” populations (e.g. West Africans and Europeans). Genetic association studies in admixed populations can be confounded by population stratification in which false-positive disease associations arise due to ancestry differences in cases and controls. In order to control for such confounding, West African ancestry was estimated in cases and controls using genetic variants called ancestry informative markers (AIMs). AIMs are markers selected based on their frequency differences between populations from different geographic regions. In the present study, “global” individual ancestry was determined for each individual using 100 AIMs selected from regions across the entire genome to estimate European and West African ancestry [20]. Using these AIMs, global individual ancestry (% West African and % European) was calculated from the genotype data using the Bayesian Markov Chain Monte Carlo (MCMC) method implemented in the program STRUCTURE 2.1 [21]. STRUCTURE 2.1 was run under the admixture model using prior population information and independent allele frequencies. The MCMC model was run using K = 2 populations (58 Europeans and 62 West Africans) and a burn-in length of 30,000 iterations followed.

Table 3. EphB2 haplotype frequencies in three major blocks

| Block | Haplotype Frequency | Frequency (Case, Control) | $X^2$ | P-Value |
|-------|----------------------|---------------------------|-------|---------|
| Block 6 rs1318720, rs4612601 | AG | 0.496 | 0.555, 0.464 | 11.59 | 0.0007 |
| | GA | 0.316 | 0.260, 0.345 | 11.55 | 0.0007 |
| | AA | 0.185 | 0.182, 0.187 | 0.05 | 0.8229 |
| Block 18 rs12074138, rs10465531 | AG | 0.573 | 0.590, 0.565 | 0.89 | 0.3456 |
| | GG | 0.232 | 0.257, 0.223 | 2.17 | 0.1401 |
| | AA | 0.194 | 0.151, 0.211 | 8.09 | 0.0044 |
| Block 19 rs12133964, rs1440576, rs4655117 | GGG | 0.394 | 0.403, 0.388 | 0.33 | 0.5632 |
| | GAG | 0.365 | 0.394, 0.355 | 2.20 | 0.1377 |
| | AGA | 0.188 | 0.147, 0.204 | 7.47 | 0.0063 |
| | GGA | 0.045 | 0.050, 0.043 | 0.41 | 0.5211 |
by 70,000 replications. These ancestry estimates were used as covariates in the regression models.

Structured Association Analyses
We tested 315 EphB2 SNPs for association with PC in our population of African Americans. We calculated odds ratios and 95% confidence intervals by performing conditional logistic regression assuming an additive effect (on the log scale) of allele dosage. We controlled for individual admixture by including West African ancestry estimates as a covariate in the logistic regression model. In addition, genetic effects were adjusted for age (at time of diagnosis for case subjects and at time of ascertainment for controls). Associations by grade (Gleason score ≤7 versus ≥8) were also examined by logistic regression in case-only analyses.

Empirical p-values, which corrected for multiple tests were generated by 100,000 permutations of the trait values in the sample using the Max (T) procedure. All analyses were done using the programs SNPGWA Version 4.0 (http://www.phs.wfubmc.edu/public/bios/gene/downloads.cfm) and PLINK [22]. Haplotype association analyses were performed using Haplovlew [23]. Clinical characteristics were compared between cases and controls by race. Two-sided t-tests were used to compare continuous variables including age and ancestry estimates. Pearson chi-square tests of independence were used to compare categorical variables.

Supporting Information

Table S1  Hardy-Weinberg Equilibrium P-values for 341 EphB2 SNPs.

Table S2  Results of Single Variant Prostate Cancer Association Analysis for 315 EphB2 SNPs.

Acknowledgments

The authors would like to thank the study participants for their involvement in this research.

Author Contributions

Conceived and designed the experiments: CMR RAK JDC. Performed the experiments: CMR SH. Analyzed the data: SH RAK. Contributed reagents/materials/analysis tools: RAK JDC. Wrote the paper: CMR SH RAK JDC.

References

1. Jemal A, Siegel R, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5): 277–300.
2. Steinberg GD, Carter BS, Beatty TH, Childs B, Walsh PC (1996) Family history and the risk of prostate cancer. Prostate 17: 337–347.
3. Gann PH (2002) Risk factors for prostate cancer. Rev Urol 4 Suppl 5: S3–S10.
4. Powell IJ, Bock CH, Rutnerbusch JF, Sakr W (2010) Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol 183: 1792–1796.
5. Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, et al. (2006) A common variant associated with prostate cancer in European and African populations. Nat Genet 38: 652–658.
6. Freedman ML, Haiman CA, Patterson N, McDonald GJ, Tandon A, et al. (2006) Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A 103: 14068–14073.
7. Robbins C, Torres JB, Hooker S, Benulla C, Hernandez W, et al. (2007) Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus. Genome Res 17: 1717–1722.
8. Xu J, Kibel AS, Hu JF, Turner AR, Pruett K, et al. (2009) Prostate cancer risk associated loci in African Americans. Cancer Epidemiol Biomarkers Prev 18: 2143–2149.
9. Bock CH, Schwarz AG, Rutnerbusch JF, Levin AM, Neshland-Deuds C, et al. (2009) Results from a prostate cancer admixture mapping study in African-American men. Hum Genet 126: 633–642.
10. Benford ML, VanClave TT, Lavender NA, Kittles RA, Kidd LR (2010) 8q24 sequence variants in relation to prostate cancer risk among men of African descent: a case-control study. BMC Cancer 10: 354.
11. Xu B, Tong N, Li JM, Zhang ZD, Wu HF (2010) ELAC2 polymorphisms and prostate cancer risk: a meta-analysis based on 18 case-control studies. Prostate Cancer Prostatic Dis 13: 270–277.
12. Deuten J, Gelfond JA, Franke JL, Shook S, Johnson-Pais TL, et al. (2010) Single and multivariate associations of MSR1, ELAC2, and RNASEL with prostate cancer in an ethnic diverse cohort of men. Cancer Epidemiol Biomarkers Prev 19: 588–599.
13. Kieffer N, Schmitz M, Scheiden R, Nathan M, Faber JC (2006) Involvement of the RNase L gene in prostate cancer. Bull Soc Med Grand Duc./Luxemb. pp 21–28.
14. Rennert H, Zeigler-Johnson CM, Addya K, Finley MJ, Walker AH, et al. (2005) Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European and African American men. Cancer Epidemiol Biomarkers Prev 14: 949–957.
15. Huisak P, Ponziano-Jackson D, Wolf M, Kiefer JA, Azorsa DO, et al. (2004) Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet 36: 979–903.
16. Oha SM, Wang YJ, Song JP, Li ZY, Kobayashi K, et al. (2001) Genomic structure and loss of heterozygosity of EPFH2 in colorectal cancer. Cancer Lett 164: 97–106.
17. Ablouzzi H, Davalos V, Kokko A, Domingo E, Woerner SM, et al. (2005) Mechanisms of inactivation of the receptor tyrosine kinase EPHB2 in colorectal tumors. Cancer Res 65: 10170–10173.
18. Kittles RA, Balloe-Bonnie AB, Moses TY, Robbins CM, Ahaghotu C, et al. (2006) A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history. J Med Genet 43: 507–511.
19. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Steu LL, et al. (2007) A second generation human haplotype map of over 3.1 million SNPs. Nature 449: 851–861.
20. Kupfer SS, Torres JB, Hooker S, Anderson JR, Skol AD, et al. (2009) Novel single nucleotide polymorphism associations with colorectal cancer on chromosome 8q24 in African and European Americans. Carcinogenesis 30: 1353–1357.
21. Falush D, Stephens M, Pritchard JK (2003) Inference of population structure and loss of heterozygosity of EPHB2 in colorectal cancer. Cancer Lett 164: 97–106.
22. Kupfer SS, Torres JB, Hooker S, Anderson JR, Skol AD, et al. (2009) Novel single nucleotide polymorphism associations with colorectal cancer on chromosome 8q24 in African and European Americans. Carcinogenesis 30: 1353–1357.
23. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559–575.
24. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haplovlew: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263–265.
25. Buchanan JA, Maller J, Daly MJ (2005) Haplovlew: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263–265.